(OH-bin-yoo-TOO-zoo-mab)
This page contains brief information about obinutuzumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Obinutuzumab is approved to be used with other drugs to treat:
- Chronic lymphocytic leukemia (CLL). It is used with chlorambucil in patients who have not yet been treated for CLL.
- Follicular lymphoma. It is used:
- With bendamustine hydrochloride and then by itself to treat follicular lymphoma that relapsed after treatment with rituximab or did not respond to the treatment.
- With chemotherapy as first-line treatment in adults with stage II bulky, stage III, or stage IV follicular lymphoma. Patients who have at least a partial remission are then treated with obinutuzumab by itself.
Obinutuzumab is also being studied in the treatment of other types of cancer.
More About Obinutuzumab
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Obinutuzumab – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Obinutuzumab – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
